» Articles » PMID: 31743686

Unique Structural and Mechanistic Properties of Mycobacterial F-ATP Synthases: Implications for Drug Design

Overview
Date 2019 Nov 20
PMID 31743686
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

The causative agent of Tuberculosis (TB) Mycobacterium tuberculosis (Mtb) encounters unfavourable environmental conditions in the lungs, including nutrient limitation, low oxygen tensions and/or low/high pH values. These harsh conditions in the host triggers Mtb to enter a dormant state in which the pathogen does not replicate and uses host-derived fatty acids instead of carbohydrates as an energy source. Independent to the energy source, the bacterium's energy currency ATP is generated by oxidative phosphorylation, in which the FF-ATP synthase uses the proton motive force generated by the electron transport chain. This catalyst is essential in Mtb and inhibition by the diarylquinoline class of drugs like Bedaquilline, TBAJ-587, TBAJ-876 or squaramides demonstrated that this engine is an attractive target in TB drug discovery. A special feature of the mycobacterial F-ATP synthase is its inability to establish a significant proton gradient during ATP hydrolysis, and its latent ATPase activity, to prevent energy waste and to control the membrane potential. Recently, unique epitopes of mycobacterial FF-ATP synthase subunits absent in their prokaryotic or mitochondrial counterparts have been identified to contribute to the regulation of the low ATPase activity. Most recent structural insights into individual subunits, the F domain or the entire mycobacterial enzyme added to the understanding of mechanisms, regulation and differences of the mycobacterial FF-ATP synthase compared to other bacterial and eukaryotic engines. These novel insights provide the basis for the design of new compounds targeting this engine and even novel regimens for multidrug resistant TB.

Citing Articles

Breaking the energy chain: importance of ATP synthase in and its potential as a drug target.

Perveen S, Pal S, Sharma R RSC Med Chem. 2025; .

PMID: 39790127 PMC: 11707528. DOI: 10.1039/d4md00829d.


F-ATP Synthase Inhibitors and Targets.

Harikishore A, Gruber G Antibiotics (Basel). 2025; 13(12.

PMID: 39766559 PMC: 11672644. DOI: 10.3390/antibiotics13121169.


The Role of Ion-Transporting Proteins in Human Disease.

Marunaka Y Int J Mol Sci. 2024; 25(3).

PMID: 38339004 PMC: 10855098. DOI: 10.3390/ijms25031726.


Molecular Mechanisms of Obesity-Induced Development of Insulin Resistance and Promotion of Amyloid-β Accumulation: Dietary Therapy Using Weak Organic Acids via Improvement of Lowered Interstitial Fluid pH.

Marunaka Y Biomolecules. 2023; 13(5).

PMID: 37238649 PMC: 10216820. DOI: 10.3390/biom13050779.


F·F ATP Synthase/ATPase: Contemporary View on Unidirectional Catalysis.

Zharova T, Grivennikova V, Borisov V Int J Mol Sci. 2023; 24(6).

PMID: 36982498 PMC: 10049701. DOI: 10.3390/ijms24065417.